Acta Neuropsychiatrica
banner
actaneuropsych.bsky.social
Acta Neuropsychiatrica
@actaneuropsych.bsky.social
Pinned
Acta Neuropsychiatrica has an open call for 2 new Special Issues!
🧠Is your paper discussing the Progress in Psychopharmacology or in Immunopsychiatry?
Final submissions are due February 1st on the Journal submission site:
cambridge.org/core/journal...
Check more details on the SI ⬇️
🩺 Building Early Pain Literacy
Pain-related knowledge can improve quality of life and satisfaction, and the sooner the better

✨In a new study, a pain neuroscience education (PNE) program significantly improved outcomes in adolescents with and without intellectual disabilities.
November 7, 2025 at 6:18 PM
🍄 What does the evidence say on Psilocybin Therapy in Depression?

📄 A new PRISMA-guided systematic review analyzed 22 clinical studies, including randomized controlled + open-label trials.

Populations included treatment-resistant depression and varied dosing and adjunctive protocols
October 27, 2025 at 2:07 PM
🧩 Rethinking Schizophrenia

Emerging evidence suggests schizophrenia has 2 biologically distinct forms:
🔹 Major Neurocognitive Psychosis (MNP)
🔹 Simple Neurocognitive Psychosis (SNP)
Both differ in immune and metabolic pathways, especially in how the brain processes tryptophan (TRP)
October 24, 2025 at 2:42 PM
Navigating the Use of Xanomeline/Trospium (Cobenfy/KarXT)
KarXT marks a significant shift as the first muscarinic

Our latest paper breaks down the key patient profiles that may benefit most from this novel mechanism of action:
doi.org/10.1017/neu....
October 17, 2025 at 11:01 AM
🎤 Voice over for measuring the physiological stress response.
What if the speech could be used as a digital biomarker of stress?

Using a validated stress-induction paradigm, researchers analyzed vocal features in relation to salivary cortisol and state anger.
October 10, 2025 at 12:10 PM
Is Clozapine use hindered?🚧A recent paper sheds light on how to transform care for treatment-resistant schizophrenia

Clozapine initiation and maintenance are hampered by misconceptions about side effects and monitoring (e.g., hospitalization/frequent tests) 🩺📋, despite confidence in the guidelines
September 25, 2025 at 1:30 PM
🔬Molecular Mechanisms of Amisulpride
New cell study reveals the complex molecular footprint of the antipsychotic amisulpride.

📊Scientists treated neuroblastoma cells with amisulpride and discovered it changes the levels of key genes and proteins involved in:👇
September 19, 2025 at 7:42 PM
📢Exciting news #CINP2026 in Glasgow will be a Joint Meeting of the Scandinavian College of Neuropsychopharmacology (SCNP) + the International College of Neuropsychopharmacology!
Join us for this unique event which promises to be an outstanding meeting of science & collaboration
@ijnp.bsky.social
September 10, 2025 at 4:39 PM
💊GLP-1 Agonists & Opioid Abuse
New translational work examines whether GLP-1 receptor agonists(GLP-1 RAs) could support treatment and/or prevention in people living with opioid use disorder(OUD)

🛡️Early evidence suggests GLP-1 RA administration was linked to reduced risk of opioid overdose in humans
September 5, 2025 at 1:22 PM
🧠✨ Psychedelics & the Neuroimmune System

A new review in Acta Neuropsychiatrica explores how 5-HT2A receptor psychedelics interact with the immune system, and how this interplay may also drive neuronal changes.
August 29, 2025 at 11:17 AM
🚨 Could AI Chatbots Worsen Mania in Bipolar Disorder?
A striking editorial suggests that chatbots may mirror and amplify the elevated mood of users prone to mania, acting like a form of "emotional contagion." 🧠

Check the editorial at: doi.org/10.1017/neu....
#DigitalMentalHealth #AIRegulation
August 22, 2025 at 1:56 PM
🧩FGF19: Linking Smoke and Mental Health 🚬

Fibroblast growth factor 19 (FGF19) regulates a wide range of biological functions (energy homeostasis, proliferation, survival, and migration) and has an emerging role as an oncology target

A recent study on FGF19 in depression and smoking revealed:
August 8, 2025 at 7:43 PM
🛤️ "The path is known by asking those who have walked it before." — Zulu proverb (South Africa)

🧠 This new study in Acta Neuropsychiatrica examined modifiable & non-modifiable factors linked to mental health changes during COVID-19.
August 1, 2025 at 4:20 PM
🌍🧠 #WorldBrainDay | July 22
Brain health is vital at every age.
From early development to aging, protecting brain function improves lives globally.
➡ 1 in 8 people live with a mental disorder, often affecting cognition, emotion & behavior.
#BrainHealthForAll #Neuropsychiatry
July 22, 2025 at 9:24 PM
A follow-up exome analysis of 270K UK #Biobank participants again found no gene-level associations with affective disorders.

Even in severe cases needing specialist referral and in this large sample, rare variant effects are likely too small and spread across many genes.
July 17, 2025 at 8:31 PM
🧠Is Internet Search a Proxy for Treatment?

No, we’re not talking about 🍕restaurants near the Pentagon. But in a similar way, Google Trends mirrors real-world ADHD prescription patterns

Researchers found that in Scandinavia (2010–2023) search trends correlate w/ADHD prescriptions
Attention-deficit hyperactivity disorder drug search trends: a Scandinavian perspective | Acta Neuropsychiatrica | Cambridge Core
Attention-deficit hyperactivity disorder drug search trends: a Scandinavian perspective - Volume 37
doi.org
July 11, 2025 at 8:59 PM
🧠 😞 Late-Life Depression (LLD)
LLD is shaped by a complex interplay of biological, psychological, and social factors + distinct clinical and biological features.
July 4, 2025 at 8:32 PM
EiC @wegener.bsky.social had the pleasure of welcoming the Associate Editor for the Special Content Section, Prof. Gin Malhi (University of Sydney), to the beautiful summer at Aarhus University.
June 20, 2025 at 1:17 PM
🧠New insights into the mechanism for the motor and #immune deficits of Kabuki syndrome

Bapa mice show ↑striatal TH, GFAP, IBA-1—linking #dopaminergic hyperactivity & #neuroinflammation.

The strain is a promising model to study motor & immune deficits

doi.org/10.1017/neu....
Behavioural impairments in a mouse model of Kabuki syndrome associated with dopaminergic and neuroinflammatory modulations | Acta Neuropsychiatrica | Cambridge Core
Behavioural impairments in a mouse model of Kabuki syndrome associated with dopaminergic and neuroinflammatory modulations - Volume 37
doi.org
May 27, 2025 at 8:26 PM
🧠 Handling the Double-Edged Sword of Antipsychotics: Wielding Precision Psychiatry
Antipsychotics like aripiprazole & risperidone are widely used—not just for psychosis but also mood & behavioral disorders.
Yet, adverse effects may hinder outcomes. 🔄
#Psychiatry #Antipsychotics
May 19, 2025 at 8:25 PM
🧠 This review just published in Acta Neuropsychiatrica explores how institutionalization in residential care affects children's brain development and mental health, through an electrophysiology perspective.

The authors found that:
May 9, 2025 at 2:52 PM
Can ACT Help Reduce Suicidality?

This new systematic review and meta-analysis examined the effectiveness of Acceptance and Commitment Therapy (ACT) on suicidality, including suicidal ideation and attempts. And the authors found that:
April 30, 2025 at 2:48 PM
Reposted by Acta Neuropsychiatrica
🧠🩺 Can #preeclampsia (PE) be addressed by assessing behavioral and metabolic changes?

A new study published in Acta Neuropsychiatrica provides evidence that neuropsychiatric symptoms in PE may be linked to immune and metabolic biomarkers.

✅Top 3 #biomarkers identified, with highlights to:
April 25, 2025 at 12:46 PM
🧠 Mild Behavioral Impairment (MBI) is a challenging sign in dementia, impacting patients, families, and clinical management.

Its early manifestation can be associated with faster cognitive decline and poorer prognosis.

🕵️‍♂️ How can we improve risk profiling in patients? 👇
April 15, 2025 at 9:25 AM